DuoResp Spiromax adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD (SPRINT)

Abstract

Background: Adherence and inhaler technique are often suboptimal in asthma and COPD. New inhalers have been developed to improve these determinants of treatment effectiveness. Aims/Objectives: To assess patient-reported adherence, satisfaction and ease of use of DuoResp® Spiromax® among SPRINT study participants. Methods: The Phase IV SPRINT study was conducted in 10 European countries. Asthma and COPD patients were receiving a fixed-dose combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA), delivered via various inhalers including DuoResp Spiromax. Primary study outcomes (asthma disease control/COPD symptom burden) are reported separately. Patients self-assessed adherence using the 8-item Morisky Medication Adherence Scale (MMAS-8©), and DuoResp Spiromax users assessed ease of use and satisfaction using 10-point scales, during a single physician’s office visit. Results: Of 1661 (asthma N=1101; COPD N=560) SPRINT study participants, 342 (asthma n=235; COPD n=107) received ICS/LABA via DuoResp Spiromax prior to inclusion. In this subset, 69.6% of asthma patients reported moderate or high adherence (MMAS-8 score ≥6). Among COPD patients using DuoResp Spiromax, 80% reported moderate or high adherence. Almost all DuoResp Spiromax users (pooled) were satisfied with their inhaler: mean (SD) satisfaction score was 8.9 (1.6); 85.4% were “very satisfied”. Mean (SD) ease of use score was 9.1 (1.3). Conclusions: Asthma and COPD patients using DuoResp Spiromax indicated that they were very satisfied with their inhaler and found it easy to use. Most DuoResp Spiromax users reported moderate or high treatment adherence.